Assessment of local adverse reactions to subcutaneous immunoglobulin (SCIG) in clinical trials
In their recent paper on the North American pivotal trial of a new 20% immunoglobulin (Ig) for subcutaneous (SC) use, Suez et al. report an incidence of local adverse events (AE) of 0.015 events/infusion and compared this to rates reported in other studies of different products. Comparison of differ...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2017
|